Ocata Therapeutics Inc (OCAT) 8.47 $OCAT Osteoa
Post# of 273242
Posted On: 09/17/2016 7:11:20 AM
Ocata Therapeutics Inc (OCAT) 8.47 $OCAT
Osteoarthritis Pipeline Market H1 2016 Global Review Report
PR Newswire - Thu Apr 28, 1:00AM CDT
New market research titled "Osteoarthritis - Pipeline Review, H1 2016" is a report that provides an overview of the Osteoarthritis's therapeutic pipeline and helps strengthen R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
MESO: 4.47 (-0.23), CBMG: 14.39 (-0.11), OCAT: 8.47 (+0.01), ZBH: 124.30 (-0.59), PFE: 33.94 (-0.20), LLY: 78.80 (-0.02), GSK: 42.88 (-0.66), GLPG: 60.38 (+1.99), AXSM: 7.35 (+0.01), OMER: 11.28 (+0.21), CANF: 2.31 (+0.03), AST: 3.95 (+0.11), AKTX: 8.80 (-0.15)
Astellas Announces Results of Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics and Changes to Subsidiaries
PR Newswire - Wed Feb 10, 8:48AM CST
Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas"
announced today that it has successfully completed, through its indirect wholly-owned subsidiary Laurel Acquisition Inc. ("Laurel" , a tender offer to purchase all issued and outstanding shares of common stock of Ocata Therapeutics, Inc. (NASDAQ: OCAT, President and CEO: Paul Wotton, "Ocata" for a price of US$8.50 per share net to the stockholder in cash ("Tender Offer" . Astellas commenced the Tender Offer on November 19, 2015, U.S. Eastern Time, and the Tender Offer, as previously extended, expired at 5:00 p.m., U.S. Eastern Time, on February 9, 2016, and was not further extended. The board of directors of Astellas approved the Tender Offer on November 10, 2015.
OCAT: 8.47 (+0.01)
Ocata Therapeutics, Inc. (NASDAQ: OCAT) Acquisition; Tender Offer Expires Today - Analyst Comments
ACCESSWIRE - Tue Feb 09, 8:02AM CST
MARLBOROUGH, MA / ACCESSWIRE / February 9, 2016 / Ocata Therapeutics, Inc. (NASDAQ: OCAT) a biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics, recently announced that Astellas has extended, through its indirect wholly-owned subsidiary Laurel Acquisition Inc., the offering period of the tender offer to purchase all issued and outstanding shares of common stock of Ocata for a price of US $8.50 per share, net to the holder in cash until 5:00 pm, U.S. Eastern Time, on February 9, 2016. The Tender Offer, as previously extended, was scheduled to expire at 5:00 pm, U.S. Eastern Time, on January 21, 2016. The further extension of the Tender Offer will allow Ocata's stockholders additional time to tender their shares into the Tender Offer. All terms and conditions of the Tender Offer shall remain unchanged during the extended offering period.
OCAT: 8.47 (+0.01)
Retinitis Pigmentosa Pipeline Review, H2 2015 Featuring 27 Companies and Respective Drug Profiles
M2 - Fri Feb 05, 4:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/pz5gtq/retinitis) has announced the addition of the "Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Retinitis Pigmentosa, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinitis Pigmentosa and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Retinitis Pigmentosa Overview - Therapeutics Development - Pipeline Products for Retinitis Pigmentosa - Overview - Pipeline Products for Retinitis Pigmentosa - Comparative Analysis - Retinitis Pigmentosa - Therapeutics under Development by Companies - Retinitis Pigmentosa - Therapeutics under Investigation by Universities/Institutes - Retinitis Pigmentosa - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Retinitis Pigmentosa - Products under Development by Companies - Retinitis Pigmentosa - Products under Investigation by Universities/Institutes - Retinitis Pigmentosa - Companies Involved in Therapeutics Development - Acucela Inc. - Amarantus Bioscience Holdings, Inc. - Applied Genetic Technologies Corporation - Asklepios BioPharmaceutical, Inc. - Caladrius Biosciences, Inc. - DNAVEC Corporation - Dompe Farmaceutici S.p.A. - Genable Technologies Limited - Genethon - GenSight Biologics SA - Grupo Ferrer Internacional, S.A. - InFlectis BioScience - International Stem Cell Corporation - Isis Pharmaceuticals, Inc. - Mimetogen Pharmaceuticals Inc. - Neurotech Pharmaceuticals, Inc. - Ocata Therapeutics, Inc. - Orphagen Pharmaceuticals, Inc. - QLT Inc. - RegenxBio Inc. - ReNeuron Group Plc - SanBio, Inc. - Sanofi - Shire Plc - Spark Therapeutics, Inc. - Sucampo Pharmaceuticals, Inc. - Sun Pharma Advanced Research Company Ltd. For more information visit http://www.researchandmarkets.com/research/pz5gtq/retinitis
OCAT: 8.47 (+0.01), QLTI: 1.58 (+0.03), ISIS: 57.56 (-0.28), ONCE: 63.85 (+1.61), SHPG: 200.60 (+4.11), SCMP: 12.33 (+0.07), GNST: (), CLBS: 5.02 (+0.01)
Astellas Extends Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics
PR Newswire - Fri Jan 22, 7:52AM CST
Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas" and Ocata Therapeutics, Inc. (NASDAQ: OCAT, President and CEO: Paul Wotton, "Ocata" today announced that Astellas has extended, through its indirect wholly-owned subsidiary Laurel Acquisition Inc., the offering period of the tender offer to purchase all issued and outstanding shares of common stock of Ocata for a price of US$8.50 per share, net to the holder in cash ("Tender Offer" until 5:00 pm, U.S. Eastern Time, on February 9, 2016. The Tender Offer, as previously extended, was scheduled to expire at 5:00 pm, U.S. Eastern Time, on January 21, 2016. The further extension of the Tender Offer will allow Ocata's stockholders additional time to tender their shares into the Tender Offer.
OCAT: 8.47 (+0.01)
Dry (Atrophic) Macular Degeneration therapeutics Pipeline Review, H2 2015
M2 - Fri Jan 22, 6:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/3cxkl2/dry_atrophic) has announced the addition of the "Dry (Atrophic) Macular Degeneration - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dry (Atrophic) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dry (Atrophic) Macular Degeneration and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Dry (Atrophic) Macular Degeneration Overview - Therapeutics Development - Pipeline Products for Dry (Atrophic) Macular Degeneration - Overview - Pipeline Products for Dry (Atrophic) Macular Degeneration - Comparative Analysis - Dry (Atrophic) Macular Degeneration - Therapeutics under Development by Companies - Dry (Atrophic) Macular Degeneration - Therapeutics under Investigation by Universities/Institutes - Dry (Atrophic) Macular Degeneration - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Dry (Atrophic) Macular Degeneration - Products under Development by Companies - Dry (Atrophic) Macular Degeneration - Products under Investigation by Universities/Institutes - Dry (Atrophic) Macular Degeneration - Companies Involved in Therapeutics Development - Aciont Inc. - Acucela Inc. - Alexion Pharmaceuticals, Inc. - Alimera Sciences, Inc. - Apellis Pharmaceuticals, Inc. - Benitec Biopharma Limited - Catalyst Biosciences, Inc. - Cell Cure Neurosciences, Ltd. - Foamix Pharmaceuticals Ltd. - Genentech, Inc. - GenSight Biologics SA - GlaxoSmithKline Plc - Icon Bioscience, Inc. - MacuCLEAR, Inc. - Novartis AG - Ocata Therapeutics, Inc. - Ophthotech Corp. - pSivida Corp. - R-Tech Ueno, Ltd. - StemCells, Inc. - Sun Pharma Advanced Research Company Ltd. - U.S. Stem Cell, Inc. For more information visit http://www.researchandmarkets.com/research/3c...y_atrophic
OCAT: 8.47 (+0.01), OPHT: 59.39 (+1.38), FOMX: 10.00 (+0.13), GNST: (), GSK: 42.88 (-0.66), ALIM: 1.61 (+0.09), ALXN: 131.46 (+1.76), CBIO: 1.25 (-0.06), NVS: 79.34 (-0.54)
Biotechnology Equities Ahead of Market -- Regulus Therapeutics, Ocata Therapeutics, Vanda Pharma, and Curis
ACCESSWIRE - Wed Dec 30, 7:01AM CST
NEW YORK, NY / ACCESSWIRE / December 30, 2015 / Park Lane Advisor has initiated coverage on the following equities: Regulus Therapeutics Inc. (NASDAQ: RGLS), Ocata Therapeutics Inc. (NASDAQ: OCAT), Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), and Curis Inc. (NASDAQ: CRIS). Free research report on Regulus Therapeutics can be accessed at http://www.parklaneadvisor.com/ On Tuesday, December 29, 2015, the NASDAQ Composite ended at 5,107.94, up 1.33%, the Dow Jones Industrial Average advanced 1.10%, to finish the day at 17,720.98, and the S&P 500 closed at 2,078.36, up 1.06%. The gains were broad based as eight out of nine sectors ended the session in positive. Register for your complimentary reports at the links given below.
CRIS: 2.02 (+0.13), OCAT: 8.47 (+0.01), VNDA: 15.55 (-0.18), RGLS: 3.23 (-0.11)
Ocata Reports the Publication of Data about the Generation of Corneal Endothelial Cells from Human Pluripotent Stem Cells
BusinessWire - Mon Dec 28, 7:00AM CST
Ocata Therapeutics, Inc. (OCAT), a leader in the field of regenerative medicine, reported today that early research was published in the journal PLOS One (online, December 21, 2015) by Ocata and its collaborators at the University of Miami, UCSD, and Stanford University. The publication presents a method for generating scalable amounts of human embryonic stem cell derived corneal endothelial cells (hESC-CEC).
OCAT: 8.47 (+0.01)
Ocata Therapeutics, Inc. Industry - Product Pipeline Review - 2015
M2 - Mon Dec 28, 5:28AM CST
Acute Market Reports's, 'Ocata Therapeutics, Inc. - Product Pipeline Review - 2015', provides an overview of the Ocata Therapeutics, Inc.'s pharmaceutical research and development focus.
OCAT: 8.47 (+0.01)
4 Stocks Under $10 Showing Great Upside Today
ACCESSWIRE - Fri Dec 18, 9:47AM CST
NEW YORK, NY / ACCESSWIRE / December 18, 2015 / MomentumStockAlert.com is a newsletter alert service that focuses on companies on the NASDAQ & NYSE. We only highlight quality companies with big potential. This commitment provides our subscribers with only the best recommendations of companies for short and long-term investments. Receive our free trade alerts via text message (SMS) and/or email at http://www.MomentumStockAlert.com. Today we are focusing on four companies to watch that have been attracting the attention of major investors.
FREE: 1.15 (-0.52), OCAT: 8.47 (+0.01), ROSG: 0.89 (-0.03), BIOD: 0.43 (+0.02)
Ocata Therapeutics (OCAT): Strong Industry, Solid Earnings Estimate Revisions
Zacks Equity Research - Zacks Investment Research - Fri Dec 18, 8:07AM CST
Ocata Therapeutics is seeing solid earnings estimate revision activity and is a great company from a Zacks Industry Rank perspective.
OCAT: 8.47 (+0.01)
Stock Updates on Biotechnology -- Xenoport, Progenics Pharma, Ocata Therapeutics, and Vanda Pharma
ACCESSWIRE - Thu Dec 17, 7:00AM CST
NEW YORK, NY / ACCESSWIRE / December 17, 2015 / Park Lane Advisor has initiated coverage on the following equities: Xenoport Inc. (NASDAQ: XNPT), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Ocata Therapeutics Inc. (NASDAQ: OCAT), and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA). Free research report on Xenoport can be accessed at http://www.parklaneadvisor.com/ On Wednesday, December 16, 2015, the NASDAQ Composite ended at 5,071.13, up 1.52%, the Dow Jones Industrial Average advanced 1.28%, to finish the day at 17,749.09, and the S&P 500 closed at 2,073.07, up 1.45%. The gains were broad based as all the sectors ended the session in positive. Register for your complimentary reports at the links given below.
OCAT: 8.47 (+0.01), PGNX: 6.10 (-0.12), VNDA: 15.55 (-0.18), XNPT: 7.07 (+0.05)
Lupus Nephritis - Pipeline Review, H2 2015
M2 - Thu Dec 17, 2:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/8jnbfq/lupus_nephritis) has announced the addition of the "Lupus Nephritis - Pipeline Review, H2 2015" report to their offering. The report provides an overview of the Lupus Nephritis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Lupus Nephritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Lupus Nephritis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Lupus Nephritis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AbbVie Inc. - Asahi Kasei Pharma Corp. - Azano Pharmaceuticals Inc. - Biogen, Inc. - Bristol-Myers Squibb Company - Deltanoid Pharmaceuticals Inc. - F. Hoffmann-La Roche Ltd. - FibroStatin SL - GlaxoSmithKline Plc - HanAll Biopharma Co., Ltd. - Invion Limited - Millennium Pharmaceuticals, Inc. - Ocata Therapeutics, Inc. - Zyrnat Biotherapeutics SL For more information visit http://www.researchandmarkets.com/research/8j..._nephritis
OCAT: 8.47 (+0.01), ABBV: 63.27 (-0.08), GSK: 42.88 (-0.66), BMY: 55.60 (-0.37)
Can Ocata Therapeutics (OCAT) Run Higher on Strong Earnings Estimate Revisions?
Zacks Equity Research - Zacks Investment Research - Wed Dec 09, 7:45AM CST
Ocata Therapeutics could be an interesting play for investors because of its positive short-term momentum and solid earnings estimate revisions
OCAT: 8.47 (+0.01)
Ocata Therapeutics Almost Doubled in November -- Here's Why
Brian Feroldi, The Motley Fool - Motley Fool - Fri Dec 04, 3:03PM CST
What: Shares of eye-disease-focused Ocata Therapeutics posted a huge 88% gain during the month of November after the company accepted a buyout offer for a healthy premium, according to data from S&P Capital IQ . So what: Early in the...
OCAT: 8.47 (+0.01)
Ocata's Hemangio-derived Mesenchymal Cells Preserve Kidney Function and Extend Lifespan in Preclinical Model of Lupus Nephritis
BusinessWire - Thu Dec 03, 7:30AM CST
Ocata Therapeutics, Inc. (NASDAQ:OCAT), a leader in the field of regenerative medicine, reported in Scientific Reports ' a Nature Group journal ' that its proprietary hemangio-derived mesenchymal cell (HMC(TM)) technology can be used to prevent the progression of fatal lupus nephritis in NZB/W F1 mice, a classic, well-studied spontaneous model for systemic lupus erythematosus (SLE).
OCAT: 8.47 (+0.01)
Harwood Feffer LLP Announces Investigation of Ocata Therapeutics, Inc.
PR Newswire - Tue Nov 24, 3:38PM CST
Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Ocata Therapeutics, Inc. ("Ocata" or the "Company" (NASDAQ: OCAT) concerning the proposed acquisition of the Company by Astellas Pharma Inc. ("Astellas" .
OCAT: 8.47 (+0.01)
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Ocata Therapeutics, Inc. of an Investigation In Connection With the Fairness of the Sale of the Company to Astellas Pharma Inc. - OCAT
ACCESSWIRE - Thu Nov 12, 4:37PM CST
NEW YORK, NY / ACCESSWIRE / November 12, 2015 / The following statement is being issued by Levi & Korsinsky, LLP:
OCAT: 8.47 (+0.01)
OCATA SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Ocata Therapeutics, Inc. (OCAT) Over the Proposed Sale of the Company to Astellas Pharma Inc.
BusinessWire - Thu Nov 12, 3:10PM CST
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Ocata Therapeutics, Inc. ("Ocata" or the "Company" (NasdaqGM:OCAT) for potential breaches of fiduciary duties in connection with the sale of the Company to Astellas Pharma Inc. for approximately $379 million.
OCAT: 8.47 (+0.01)
OCATA THERAPEUTICS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Merger with Astellas Pharma Inc.
BusinessWire - Wed Nov 11, 12:09PM CST
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Ocata Therapeutics, Inc. ("Ocata" (NasdaqGM: OCAT) concerning the merger with Astellas Pharma Inc. Under the terms of the agreement, valued at approximately $379 million, Ocata shareholders will only receive $8.50 per share held.
OCAT: 8.47 (+0.01)
Osteoarthritis Pipeline Market H1 2016 Global Review Report
PR Newswire - Thu Apr 28, 1:00AM CDT
New market research titled "Osteoarthritis - Pipeline Review, H1 2016" is a report that provides an overview of the Osteoarthritis's therapeutic pipeline and helps strengthen R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
MESO: 4.47 (-0.23), CBMG: 14.39 (-0.11), OCAT: 8.47 (+0.01), ZBH: 124.30 (-0.59), PFE: 33.94 (-0.20), LLY: 78.80 (-0.02), GSK: 42.88 (-0.66), GLPG: 60.38 (+1.99), AXSM: 7.35 (+0.01), OMER: 11.28 (+0.21), CANF: 2.31 (+0.03), AST: 3.95 (+0.11), AKTX: 8.80 (-0.15)
Astellas Announces Results of Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics and Changes to Subsidiaries
PR Newswire - Wed Feb 10, 8:48AM CST
Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas"
announced today that it has successfully completed, through its indirect wholly-owned subsidiary Laurel Acquisition Inc. ("Laurel" , a tender offer to purchase all issued and outstanding shares of common stock of Ocata Therapeutics, Inc. (NASDAQ: OCAT, President and CEO: Paul Wotton, "Ocata" for a price of US$8.50 per share net to the stockholder in cash ("Tender Offer" . Astellas commenced the Tender Offer on November 19, 2015, U.S. Eastern Time, and the Tender Offer, as previously extended, expired at 5:00 p.m., U.S. Eastern Time, on February 9, 2016, and was not further extended. The board of directors of Astellas approved the Tender Offer on November 10, 2015. OCAT: 8.47 (+0.01)
Ocata Therapeutics, Inc. (NASDAQ: OCAT) Acquisition; Tender Offer Expires Today - Analyst Comments
ACCESSWIRE - Tue Feb 09, 8:02AM CST
MARLBOROUGH, MA / ACCESSWIRE / February 9, 2016 / Ocata Therapeutics, Inc. (NASDAQ: OCAT) a biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics, recently announced that Astellas has extended, through its indirect wholly-owned subsidiary Laurel Acquisition Inc., the offering period of the tender offer to purchase all issued and outstanding shares of common stock of Ocata for a price of US $8.50 per share, net to the holder in cash until 5:00 pm, U.S. Eastern Time, on February 9, 2016. The Tender Offer, as previously extended, was scheduled to expire at 5:00 pm, U.S. Eastern Time, on January 21, 2016. The further extension of the Tender Offer will allow Ocata's stockholders additional time to tender their shares into the Tender Offer. All terms and conditions of the Tender Offer shall remain unchanged during the extended offering period.
OCAT: 8.47 (+0.01)
Retinitis Pigmentosa Pipeline Review, H2 2015 Featuring 27 Companies and Respective Drug Profiles
M2 - Fri Feb 05, 4:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/pz5gtq/retinitis) has announced the addition of the "Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Retinitis Pigmentosa, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinitis Pigmentosa and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Retinitis Pigmentosa Overview - Therapeutics Development - Pipeline Products for Retinitis Pigmentosa - Overview - Pipeline Products for Retinitis Pigmentosa - Comparative Analysis - Retinitis Pigmentosa - Therapeutics under Development by Companies - Retinitis Pigmentosa - Therapeutics under Investigation by Universities/Institutes - Retinitis Pigmentosa - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Retinitis Pigmentosa - Products under Development by Companies - Retinitis Pigmentosa - Products under Investigation by Universities/Institutes - Retinitis Pigmentosa - Companies Involved in Therapeutics Development - Acucela Inc. - Amarantus Bioscience Holdings, Inc. - Applied Genetic Technologies Corporation - Asklepios BioPharmaceutical, Inc. - Caladrius Biosciences, Inc. - DNAVEC Corporation - Dompe Farmaceutici S.p.A. - Genable Technologies Limited - Genethon - GenSight Biologics SA - Grupo Ferrer Internacional, S.A. - InFlectis BioScience - International Stem Cell Corporation - Isis Pharmaceuticals, Inc. - Mimetogen Pharmaceuticals Inc. - Neurotech Pharmaceuticals, Inc. - Ocata Therapeutics, Inc. - Orphagen Pharmaceuticals, Inc. - QLT Inc. - RegenxBio Inc. - ReNeuron Group Plc - SanBio, Inc. - Sanofi - Shire Plc - Spark Therapeutics, Inc. - Sucampo Pharmaceuticals, Inc. - Sun Pharma Advanced Research Company Ltd. For more information visit http://www.researchandmarkets.com/research/pz5gtq/retinitis
OCAT: 8.47 (+0.01), QLTI: 1.58 (+0.03), ISIS: 57.56 (-0.28), ONCE: 63.85 (+1.61), SHPG: 200.60 (+4.11), SCMP: 12.33 (+0.07), GNST: (), CLBS: 5.02 (+0.01)
Astellas Extends Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics
PR Newswire - Fri Jan 22, 7:52AM CST
Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas"
and Ocata Therapeutics, Inc. (NASDAQ: OCAT, President and CEO: Paul Wotton, "Ocata" today announced that Astellas has extended, through its indirect wholly-owned subsidiary Laurel Acquisition Inc., the offering period of the tender offer to purchase all issued and outstanding shares of common stock of Ocata for a price of US$8.50 per share, net to the holder in cash ("Tender Offer" until 5:00 pm, U.S. Eastern Time, on February 9, 2016. The Tender Offer, as previously extended, was scheduled to expire at 5:00 pm, U.S. Eastern Time, on January 21, 2016. The further extension of the Tender Offer will allow Ocata's stockholders additional time to tender their shares into the Tender Offer. OCAT: 8.47 (+0.01)
Dry (Atrophic) Macular Degeneration therapeutics Pipeline Review, H2 2015
M2 - Fri Jan 22, 6:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/3cxkl2/dry_atrophic) has announced the addition of the "Dry (Atrophic) Macular Degeneration - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dry (Atrophic) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dry (Atrophic) Macular Degeneration and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Dry (Atrophic) Macular Degeneration Overview - Therapeutics Development - Pipeline Products for Dry (Atrophic) Macular Degeneration - Overview - Pipeline Products for Dry (Atrophic) Macular Degeneration - Comparative Analysis - Dry (Atrophic) Macular Degeneration - Therapeutics under Development by Companies - Dry (Atrophic) Macular Degeneration - Therapeutics under Investigation by Universities/Institutes - Dry (Atrophic) Macular Degeneration - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Dry (Atrophic) Macular Degeneration - Products under Development by Companies - Dry (Atrophic) Macular Degeneration - Products under Investigation by Universities/Institutes - Dry (Atrophic) Macular Degeneration - Companies Involved in Therapeutics Development - Aciont Inc. - Acucela Inc. - Alexion Pharmaceuticals, Inc. - Alimera Sciences, Inc. - Apellis Pharmaceuticals, Inc. - Benitec Biopharma Limited - Catalyst Biosciences, Inc. - Cell Cure Neurosciences, Ltd. - Foamix Pharmaceuticals Ltd. - Genentech, Inc. - GenSight Biologics SA - GlaxoSmithKline Plc - Icon Bioscience, Inc. - MacuCLEAR, Inc. - Novartis AG - Ocata Therapeutics, Inc. - Ophthotech Corp. - pSivida Corp. - R-Tech Ueno, Ltd. - StemCells, Inc. - Sun Pharma Advanced Research Company Ltd. - U.S. Stem Cell, Inc. For more information visit http://www.researchandmarkets.com/research/3c...y_atrophic
OCAT: 8.47 (+0.01), OPHT: 59.39 (+1.38), FOMX: 10.00 (+0.13), GNST: (), GSK: 42.88 (-0.66), ALIM: 1.61 (+0.09), ALXN: 131.46 (+1.76), CBIO: 1.25 (-0.06), NVS: 79.34 (-0.54)
Biotechnology Equities Ahead of Market -- Regulus Therapeutics, Ocata Therapeutics, Vanda Pharma, and Curis
ACCESSWIRE - Wed Dec 30, 7:01AM CST
NEW YORK, NY / ACCESSWIRE / December 30, 2015 / Park Lane Advisor has initiated coverage on the following equities: Regulus Therapeutics Inc. (NASDAQ: RGLS), Ocata Therapeutics Inc. (NASDAQ: OCAT), Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), and Curis Inc. (NASDAQ: CRIS). Free research report on Regulus Therapeutics can be accessed at http://www.parklaneadvisor.com/ On Tuesday, December 29, 2015, the NASDAQ Composite ended at 5,107.94, up 1.33%, the Dow Jones Industrial Average advanced 1.10%, to finish the day at 17,720.98, and the S&P 500 closed at 2,078.36, up 1.06%. The gains were broad based as eight out of nine sectors ended the session in positive. Register for your complimentary reports at the links given below.
CRIS: 2.02 (+0.13), OCAT: 8.47 (+0.01), VNDA: 15.55 (-0.18), RGLS: 3.23 (-0.11)
Ocata Reports the Publication of Data about the Generation of Corneal Endothelial Cells from Human Pluripotent Stem Cells
BusinessWire - Mon Dec 28, 7:00AM CST
Ocata Therapeutics, Inc. (OCAT), a leader in the field of regenerative medicine, reported today that early research was published in the journal PLOS One (online, December 21, 2015) by Ocata and its collaborators at the University of Miami, UCSD, and Stanford University. The publication presents a method for generating scalable amounts of human embryonic stem cell derived corneal endothelial cells (hESC-CEC).
OCAT: 8.47 (+0.01)
Ocata Therapeutics, Inc. Industry - Product Pipeline Review - 2015
M2 - Mon Dec 28, 5:28AM CST
Acute Market Reports's, 'Ocata Therapeutics, Inc. - Product Pipeline Review - 2015', provides an overview of the Ocata Therapeutics, Inc.'s pharmaceutical research and development focus.
OCAT: 8.47 (+0.01)
4 Stocks Under $10 Showing Great Upside Today
ACCESSWIRE - Fri Dec 18, 9:47AM CST
NEW YORK, NY / ACCESSWIRE / December 18, 2015 / MomentumStockAlert.com is a newsletter alert service that focuses on companies on the NASDAQ & NYSE. We only highlight quality companies with big potential. This commitment provides our subscribers with only the best recommendations of companies for short and long-term investments. Receive our free trade alerts via text message (SMS) and/or email at http://www.MomentumStockAlert.com. Today we are focusing on four companies to watch that have been attracting the attention of major investors.
FREE: 1.15 (-0.52), OCAT: 8.47 (+0.01), ROSG: 0.89 (-0.03), BIOD: 0.43 (+0.02)
Ocata Therapeutics (OCAT): Strong Industry, Solid Earnings Estimate Revisions
Zacks Equity Research - Zacks Investment Research - Fri Dec 18, 8:07AM CST
Ocata Therapeutics is seeing solid earnings estimate revision activity and is a great company from a Zacks Industry Rank perspective.
OCAT: 8.47 (+0.01)
Stock Updates on Biotechnology -- Xenoport, Progenics Pharma, Ocata Therapeutics, and Vanda Pharma
ACCESSWIRE - Thu Dec 17, 7:00AM CST
NEW YORK, NY / ACCESSWIRE / December 17, 2015 / Park Lane Advisor has initiated coverage on the following equities: Xenoport Inc. (NASDAQ: XNPT), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Ocata Therapeutics Inc. (NASDAQ: OCAT), and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA). Free research report on Xenoport can be accessed at http://www.parklaneadvisor.com/ On Wednesday, December 16, 2015, the NASDAQ Composite ended at 5,071.13, up 1.52%, the Dow Jones Industrial Average advanced 1.28%, to finish the day at 17,749.09, and the S&P 500 closed at 2,073.07, up 1.45%. The gains were broad based as all the sectors ended the session in positive. Register for your complimentary reports at the links given below.
OCAT: 8.47 (+0.01), PGNX: 6.10 (-0.12), VNDA: 15.55 (-0.18), XNPT: 7.07 (+0.05)
Lupus Nephritis - Pipeline Review, H2 2015
M2 - Thu Dec 17, 2:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/8jnbfq/lupus_nephritis) has announced the addition of the "Lupus Nephritis - Pipeline Review, H2 2015" report to their offering. The report provides an overview of the Lupus Nephritis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Lupus Nephritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Lupus Nephritis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Lupus Nephritis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AbbVie Inc. - Asahi Kasei Pharma Corp. - Azano Pharmaceuticals Inc. - Biogen, Inc. - Bristol-Myers Squibb Company - Deltanoid Pharmaceuticals Inc. - F. Hoffmann-La Roche Ltd. - FibroStatin SL - GlaxoSmithKline Plc - HanAll Biopharma Co., Ltd. - Invion Limited - Millennium Pharmaceuticals, Inc. - Ocata Therapeutics, Inc. - Zyrnat Biotherapeutics SL For more information visit http://www.researchandmarkets.com/research/8j..._nephritis
OCAT: 8.47 (+0.01), ABBV: 63.27 (-0.08), GSK: 42.88 (-0.66), BMY: 55.60 (-0.37)
Can Ocata Therapeutics (OCAT) Run Higher on Strong Earnings Estimate Revisions?
Zacks Equity Research - Zacks Investment Research - Wed Dec 09, 7:45AM CST
Ocata Therapeutics could be an interesting play for investors because of its positive short-term momentum and solid earnings estimate revisions
OCAT: 8.47 (+0.01)
Ocata Therapeutics Almost Doubled in November -- Here's Why
Brian Feroldi, The Motley Fool - Motley Fool - Fri Dec 04, 3:03PM CST
What: Shares of eye-disease-focused Ocata Therapeutics posted a huge 88% gain during the month of November after the company accepted a buyout offer for a healthy premium, according to data from S&P Capital IQ . So what: Early in the...
OCAT: 8.47 (+0.01)
Ocata's Hemangio-derived Mesenchymal Cells Preserve Kidney Function and Extend Lifespan in Preclinical Model of Lupus Nephritis
BusinessWire - Thu Dec 03, 7:30AM CST
Ocata Therapeutics, Inc. (NASDAQ:OCAT), a leader in the field of regenerative medicine, reported in Scientific Reports ' a Nature Group journal ' that its proprietary hemangio-derived mesenchymal cell (HMC(TM)) technology can be used to prevent the progression of fatal lupus nephritis in NZB/W F1 mice, a classic, well-studied spontaneous model for systemic lupus erythematosus (SLE).
OCAT: 8.47 (+0.01)
Harwood Feffer LLP Announces Investigation of Ocata Therapeutics, Inc.
PR Newswire - Tue Nov 24, 3:38PM CST
Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Ocata Therapeutics, Inc. ("Ocata" or the "Company"
(NASDAQ: OCAT) concerning the proposed acquisition of the Company by Astellas Pharma Inc. ("Astellas" . OCAT: 8.47 (+0.01)
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Ocata Therapeutics, Inc. of an Investigation In Connection With the Fairness of the Sale of the Company to Astellas Pharma Inc. - OCAT
ACCESSWIRE - Thu Nov 12, 4:37PM CST
NEW YORK, NY / ACCESSWIRE / November 12, 2015 / The following statement is being issued by Levi & Korsinsky, LLP:
OCAT: 8.47 (+0.01)
OCATA SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Ocata Therapeutics, Inc. (OCAT) Over the Proposed Sale of the Company to Astellas Pharma Inc.
BusinessWire - Thu Nov 12, 3:10PM CST
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Ocata Therapeutics, Inc. ("Ocata" or the "Company"
(NasdaqGM:OCAT) for potential breaches of fiduciary duties in connection with the sale of the Company to Astellas Pharma Inc. for approximately $379 million. OCAT: 8.47 (+0.01)
OCATA THERAPEUTICS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Merger with Astellas Pharma Inc.
BusinessWire - Wed Nov 11, 12:09PM CST
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Ocata Therapeutics, Inc. ("Ocata"
(NasdaqGM: OCAT) concerning the merger with Astellas Pharma Inc. Under the terms of the agreement, valued at approximately $379 million, Ocata shareholders will only receive $8.50 per share held. OCAT: 8.47 (+0.01)
(0)
(0)Scroll down for more posts ▼